PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2

Completed · Phase 1

Conditions studied: CB1, Cannabinoid, PET, Brain Imaging

In brief

The purpose of this protocol is to measure brain CB1 receptors in the hope to better understand how they work, so that one day we can understand how the CB1 receptors are involved in psychiatric, neurological, and behavioral disorders.

Key facts

Study ID

NCT00598286

Run by

National Institute of Mental Health (NIMH)

People needed

18

Starts

2008-01-01

Expected to finish

2009-10-01

Last updated by the study team

2017-10-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Current psychiatric illness, substance abuse including marijuana use, or severe systemic disease based on history and physical exam.
• Laboratory tests with clinically significant abnormalities or positive urine toxicology screen.
• Prior participation in other research protocols in the last year such that radiation exposure would exceed the annual limits.
• Pregnancy and breast feeding.
• Claustrophobia.
• Presence of ferromagnetic metal in the body or heart pacemaker.
• Positive HIV test.
• Employee of the investigative site or an immediate family member of an employee of the investigative site. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
• Employee of Eli Lilly and Company.

Where it is running

• National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.